MedTrace Logo

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

NCT01674205 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-12-15

No results posted yet for this study

Summary

This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic live attenuated influenza vaccine (LAIV) in humans and to develop biomarkers that can predict the viral shedding and immune response to LAIVs.

Conditions

  • Influenza, Human

Interventions

BIOLOGICAL

A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)

BIOLOGICAL

A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)

BIOLOGICAL

2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)

BIOLOGICAL

Vaccine placebo (Leibovitz-15 [L-15])

BIOLOGICAL

Vaccine placebo (FluMist®)

Sponsors & Collaborators

  • University of Rochester

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • John Treanor, MD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01674205 on ClinicalTrials.gov